Fundraising FoxLysosomal Therapeutics
Cambridge, US · Founded 2011 · Delaware corporation · 6 known investors
Find your way into Lysosomal Therapeutics
Sign up to find every way you can get introduced to Lysosomal Therapeutics
- Your email: who you already know at Lysosomal Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Lysosomal Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Lysosomal Therapeutics Inc. (LTI) develops small-molecule drug therapies for severe neurological diseases affecting movement and cognition, with a lead candidate, LTI-291, targeting GBA-associated parkinsonism, a form of Parkinson's disease linked to GBA1 gene mutations. The company's drug discovery approach draws on the biological link between common neurodegenerative diseases and rare lysosomal genetic disorders.
Founders & leadership
Lysosomal Therapeutics was founded in 2011 by Dimitri Krainc.
Board
Investors · 6
How we know: Sanofi Ventures's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$38M disclosed across 4 rounds · 2014–2019
▶$1MraisedNov 2019 · 10 investors · BiotechnologyRule 506(b)
- Steven E. HallDirector
- Carole NuechterleinDirector
- Clay ThorpDirector
- Daniel GeffkenExecutive Officer
- Bruce L. BoothDirector
- Robert CarpenterExecutive Officer, Director
- Cornelis BeenExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26.1MraisedJan 2017 · 9 investors · BiotechnologyRule 506(b)
- Steven HallDirector
- Bernard DavitianDirector
- Daniel GeffkenExecutive Officer
- Bruce BoothDirector
- Cornelis BeenExecutive Officer, Director
- Robert CarpenterExecutive Officer, Director
- Carole NeuchterleinDirector
- Clay ThorpDirector
- Offering amount
- $26.1M
- Amount sold
- $26.1M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedOct 2016 · 9 investors · BiotechnologyRule 506(b)
- Steven HallDirector
- Carole NuechterleinDirector
- Bernard DavitianDirector
- Robert CarpenterExecutive Officer, Director
- Bruce BoothDirector
- Cornelis BeenExecutive Officer, Director
- Clay ThorpDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Proceeds to insiders
- $250K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$4.8MraisedMay 2014 · 11 investors · PharmaceuticalsRule 506(b)
- Dimitri KraincDirector
- Cornelis BeenExecutive Officer, Director
- Robert CarpenterExecutive Officer, Director
- Henri TermeerDirector
- Peter WirthDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Lysosomal Therapeutics do?
- Lysosomal Therapeutics Inc. (LTI) develops small-molecule drug therapies for severe neurological diseases affecting movement and cognition, with a lead candidate, LTI-291, targeting GBA-associated parkinsonism, a form of Parkinson's disease linked to GBA1 gene mutations. The company's drug discovery approach draws on the biological link between common neurodegenerative diseases and rare lysosomal genetic disorders.
- Who founded Lysosomal Therapeutics?
- Lysosomal Therapeutics was founded by Dimitri Krainc in 2011.
- Who are Lysosomal Therapeutics's investors?
- Lysosomal Therapeutics's investors include Sanofi Ventures, Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Omega Funds, Roche Venture Fund.
- How much funding has Lysosomal Therapeutics raised?
- Lysosomal Therapeutics has disclosed $38M raised across 4 rounds.
- Where is Lysosomal Therapeutics headquartered?
- Lysosomal Therapeutics is headquartered in Cambridge, US.